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Edited by Richard CogdellAbstract Although ﬂavodoxin I is indispensable for Escherichia
coli growth, the exact pathway(s) where ﬂavodoxin I is essential
has not been identiﬁed. We performed transposon mutagenesis of
the ﬂavodoxin I gene, ﬂdA, in an E. coli strain that expressed
mevalonate pathway enzymes and that had a point mutation in
the lytB gene of the MEP pathway resulting in the accumula-
tion of (E)-4-hydroxy-3-methylbutyl-2-enyl pyrophosphate
(HMBPP). Disruption of ﬂdA abrogated mevalonate-indepen-
dent growth and dramatically decreased HMBPP levels. The
ﬂdA mutant grew with mevalonate indicating that the essential
role of ﬂavodoxin I under aerobic conditions is in the MEP path-
way. Growth was restored by ﬂdA complementation. Since GcpE
(which synthesizes HMBPP) and LytB are iron–sulfur enzymes
that require a reducing system for their activity, we propose that
ﬂavodoxin is essential for GcpE and possibly LytB activity.
Thus, the essential role for ﬂavodoxin I in E. coli is in the
MEP pathway for isoprenoid biosynthesis.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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cd T cell1. Introduction
Two metabolic pathways exist for isoprenoid biosynthesis:
the classical mevalonate pathway found ubiquitously in mam-
malian cells and Archaebacteria and the recently discovered 2-
C-methyl-D-erythritol 4-phosphate (MEP) pathway (also
termed the deoxyxylulose pathway) [1–3]. The MEP pathway
is present in most Eubacteria, plant chloroplasts, and the api-
coplasts of Apicomplexan protozoa such as Plasmodium andAbbreviations: DMAPP, dimethylallyl pyrophosphate; IPP, isopente-
nyl pyrophosphate; MEP, 2-C-methyl-D-erythritol 4-phosphate;
HMBPP, (E)-4-hydroxy-3-methylbutyl-2-enyl pyrophosphate; LB,
Luria-Bertani; MVA, mevalonate; PBS, phosphate buﬀered saline
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doi:10.1016/j.febslet.2005.05.047Toxoplasma [4]. Both pathways lead to the synthesis of two
essential metabolic precursors for isoprenoid biosynthesis, iso-
pentenyl pyrophosphate (IPP) and dimethylallyl pyrophos-
phate (DMAPP). The MEP pathway consists of 7 enzymes.
The last two enzymes, GcpE [5–7] and LytB [8], are the most
unusual because their functional activities are rapidly inacti-
vated by dioxygen and thus are dependent on the presence of
exogenous reducing agents for their enzymatic activity (re-
viewed in [4]). Seemann et al. [9] has reported that GcpE in
E. coli consists of a dioxygen-sensitive [4Fe–4S]2+ cluster that
is required for the catalytic reduction of 2-C-methyl-D-erythri-
tol cyclopyrophosphate into (E)-4-hydroxy-3-methylbutyl-2-
enyl pyrophosphate (HMBPP).
HMBPP is a potent activator of human Vc2Vd2 T cells
([10,11], and reviewed in [12]) and the presence of HMBPP cor-
relates with the ability of microbes to stimulate Vc2Vd2 T cells
in vitro and in vivo ([13], and reviewed in [14]). Similarly, the
conversion of HMBPP to IPP and DMAPP by the down-
stream enzyme, LytB, also strictly depends on the presence
of reducing agents for its action [15]. Further studies on LytB
using UV/Vis absorption and electron paramagnetic resonance
reveal that it too contains a [4Fe–4S] cluster [16,17]. Thus, it
has been suggested that these [Fe–S] clusters in GcpE and LytB
participate in the electron transfer process maintained under a
reducing environment.
A common characteristic shared by many iron–sulfur pro-
teins is the requirement for a reducing system that permits
the regeneration of reduced [Fe–S]+ clusters. The reduction
of oxidized [Fe–S]2+ could be achieved using dithionite or a
stronger reductant, deazaﬂavin [15]. Alternatively, this reduc-
tion can be provided using the endogenous ﬂavodoxin/ﬂavo-
doxin reductase/NADPH reducing system present in
prokaryotes, and in red and green algae. Flavodoxins com-
prise a family of small molecular weight electron transferases
important for a variety for metabolic processes including
nitrogen ﬁxation, carbon dioxide ﬁxation, and anaerobic
metabolism. Two types of ﬂavodoxins exist in E. coli. Flavo-
doxin I is encoded by ﬂdA and is constitutively expressed in
E. coli whereas ﬂavodoxin II is encoded by ﬂdB and is in-
duced by oxidative stress [18]. Flavodoxin I has been shown
to be an essential gene in E. coli. Flavodoxin II cannot re-
place ﬂavodoxin I [18]. However, the metabolic pathway
where ﬂavodoxin I is essential is unknown. Here, we report
that transposon-mediated mutagenesis of ﬂdA demonstrates
that ﬂavodoxin I plays an essential role in the MEP isopren-
oid biosynthetic pathway.blished by Elsevier B.V. All rights reserved.
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2.1. Construction of the DK310 idi-disruptant
Bacteria strains and plasmids used in this study are detailed in Sup-
plemental Table 1. On the basis of the nucleotide sequence of the IPP
isomerase gene, idi, from E. coli W3110, two oligonucleotide primers,
5 0-GGAAGCTTACATGATGCTTCATGGTTTG-3 0 (upstream of 5 0
of idi) and 5 0-GGAAGCTTTGGGAAGTTGAAACGCCGATG-30
(downstream of 3 0 of idi), including a HindIII restriction site (under-
lined) were synthesized (Sigma, St. Louis, MO) and used together with
total DNA from E. coli W3110 to amplify idi. By using Taq DNA
polymerase (Roche Molecular Biochemicals, Indianapolis, IN) and
the protocol recommended by the supplier, a 2.5-kb fragment includ-
ing the idi gene was ampliﬁed. The PCR fragment was digested with
HindIII and cloned into the multi-cloning site of an E. coli vector
pUC118 to give pUIDI.
An idi-disruptant, DK310, was constructed by insertion of the Cmr
gene (a chloramphenicol-resistance gene) into the idi gene. Cmr gene
was digested with Aor51HI from pACYC184 to provide a 1.3-kb
DNA fragment carrying the Cmr gene, which encoded chlorampheni-
col acetyltransferase. pUIDI was digested with SpeI, the recognition
site of which was in the targeted idi gene, treated with T4 DNA poly-
merase, and then ligated with the 1.3-kb DNA fragment carrying the
Cmr gene to construct pUIDICM. A 3.8-kb linear HindIII–HindIII
fragment carrying idi and Cmr genes was isolated from pUIDICM.
E. coli FS1576, a recD mutant, was transformed with the HindIII–Hin-
dIII fragment and then chloramphenicol-resistant transformants were
selected on Luria-Bertani (LB) plates containing 17 lg chlorampheni-
col/ml. After the correct disruption was conﬁrmed by Southern hybrid-
ization using the idi and Cmr genes as the probes, the disrupted idi gene
was then transduced to E. coli W3110 (wild-type) using bacteriophage
P1. The resulting W3110 idi::Cmr strain was named DK310.
2.2. Construction of DK310 (idi) LytBG120D mutant strains
The idi disruptant strain, DK310, was treated with N-methyl-N 0-
nitro-N-nitrosoguanidine as previously described [19]. After the treat-
ment, DK310 was transformed with the pTMV22KM plasmid that
contains the genes for mevalonate kinase, phosphomevalonate kinase,
and diphosphomevalonate decarboxylase all from Streptomyces sp.
strain CL190 [20,21]. A mutant in the lytB gene was then isolated by
screening 20000 colonies for colonies that required mevalonate for
growth. The point mutation changed glycine to aspartic acid at posi-
tion 120 (GGTﬁ GAT). This strain was named DK310 LytBG120D
(pTMV22KM). A second strain, DK310 LytBG120D (pTMV20KM),
was developed from this strain by transformation with pTMV20KM
and selection on an LB plate containing CM and KM. The
pTMV20KM plasmid contains the Streptomyces sp. genes for mevalo-
nate kinase, phosphomevalonate kinase, diphosphomevalonate decar-
boxylase, and isopentenyl diphosphate isomerase. The growth
properties of the two strains at 37 C in LB liquid medium for 12 h
are shown in Table 1.
2.3. Generation of DK310 LytBG120D ﬂdA mutant strain
An ﬂdA mutant E. coli strain was generated by transposon-mediated
mutagenesis of the DK310 LytBG120D (pTMV20KM) bacteria. The
bacteria were grown in LB broth to an optimal density of 0.3, chilled
immediately, centrifuged, and washed three times with ice-cold 10%Table 1
Growth properties of the DK310 LytBG120D mutantsa




CMb and KMc  ++
CM, KM, and MVAd ++ ++




aBacteria were grown in LB liquid medium for 12 h at 37 C.
bChloramphenicol was present at 34 lg/ml.
cKanamycin was present at 25 lg/ml.
dMevalonolactone was present at 0.01%.
eFosmidomycin was present at 12.5 lg/ml.glycerol. The resulting pellet was re-suspended in medium containing
10% glycerol, 0.125% (w/v) yeast extract and 0.25% (w/v) tryptone,
and stored at 80 C. Fifty microliter of these electrocompetent bacte-
ria was mixed with 1 ll of EZ:TNe ÆDHFR-1æ Tnp Transposomee
(Epicentre, Madison, WI) and transferred to a 0.2 cm electrode cur-
vette. Transposome were electroporated into bacterial cells using a
Gene Pulser II electroporator (Biorad, Burlingame, CA) set at
2500 V, 200 X, and 25 lF. One milliliter of SOC medium was immedi-
ately added to the bacteria after electroporation. The bacteria were
incubated at 37 C for 1 h with gentle agitation. The transposed bacte-
ria were spread on LB plate containing 50 lg/ml trimethoprim and
1 mg/ml mevalonolactone (Sigma) at 37 C overnight. Bacterial mu-
tants, thus, generated were arrayed in a 96 well format and screened
for the loss of bioactivity with a Vc2Vd2 T cell clone and for their abil-
ity to grow in the absence of mevalonate. To ensure the complete loss
of activity, bacteria were further grown at room temperature for 4–7
days. Genomic DNA was isolated from mutants using a MasterPuree
DNA puriﬁcation kit (Epicentre) and directly sequenced with a pair of
primers speciﬁc to each end of the transposon at the University of
Iowa DNA sequencing facility. DHFR-1 forward primer:
GGCGGAAACATTGGATGCGG; DHFR-2 reverse primer: GAC-
ACTCTGTTATTACAAATCG. The genomic transposition sites were
located using BLAST programs maintained at the NCBI web site of
the National Library of Medicine (http://www.ncbi.nlm.nih.gov/
BLAST/). The ﬂdA mutant had a transposon inserted into the ﬂdA
coding sequence at nucleotide 39.
2.4. Complementation of the ﬂdA mutant
To complement the DK310 LytBG120D ﬂdA (pTMV20KM) mu-
tant, the ﬂdA gene was cloned from E. coli into the low-copy vector,
pMW118, at the BamHI site to derive the plasmid, pMW-ﬂdA. The in-
sert, containing the upstream sequence and the full coding sequence of
the ﬂdA gene, is given in Supplemental Figure 1. The DK310
LytBG120D ﬂdA (pTMV20KM) mutant was transformed with the
pMW-ﬂdA plasmid by electroporation as described above. Transfor-
mants were selected by resistance to ampicillin and trimethoprim and
then tested for their growth with and without mevalonate.
2.5. Preparing bacterial supernatants and sonicates
To test bacterial supernatants and sonicates for their ability to stim-
ulate Vc2Vd2 T cells, E. coli bacteria were grown in 1 L of LB media in
2.6 L ﬂuted Fernback ﬂasks to late stationary phase by incubating for
24 h at 37 C in an Innova 4400 shaker oscillating at 225 rev/min.
This was found to result in the maximum amount of bioactivity. The
bacteria were harvested by centrifugation at 380 · g for 15 min at
4 C. The culture supernatant was removed and the bacteria washed
twice with phosphate buﬀered saline (PBS). Bacteria from 1 L of cul-
ture were suspended in 10 ml of PBS and continuously probe sonicated
for 10 min on ice at a 4.5 setting (Sonic Dismembrator Model 550,
Fisher Scientiﬁc). The sonicated bacteria were centrifuged at 300 · g
for 15 min at 4 C. The supernatants from the sonicated bacteria and
the culture supernatants were heated in a boiling water bath for
5 min, cooled on ice for 5 min, centrifuged at 16000 · g for 30 min
at 4 C, ﬁlter sterilized with a 0.22 lm ﬁlter, and frozen at 80 C.
The heating caused precipitation of protein and other bacterial compo-
nents that inhibit T cell proliferation but did not aﬀect the overall bio-
activity for Vc2Vd2 T cells.
2.6. Assaying bioactivity for Vc2Vc2 T cells
The 12G12, DG.SF68, and CP.1.15 Vc2Vd2 T cell clones used in this
study have been described [22]. Vc2Vd2 T cell clones were propagated
by periodic re-stimulation as described [23]. Brieﬂy, 2.5–5 · 105 T cells
were cultured with irradiated PBMC (2.5 · 105) from healthy donors,
EBV-transformed B cells (DG.EBV and CP.EBV each at 2.5 · 105)
and PHA (1:2000) in RPMI 1640 supplemented with rIL-2 (1 nM).
For assaying bioactivity, 5–10 · 104 Vc2Vd2 T cells were cultured
with 5–10 · 104 mitomycin C-treated Va-2 cells (a transformed human
ﬁbrosarcoma cell line) as antigen presenting cells in 200 ll of complete
medium (RPMI 1640 with 8% FBS, L-glutamine, sodium pyruvate,
non-essential, essential MEM amino acids, HEPES, and b-mercap-
toethanol). Culture supernatants and bacterial sonicates were added
to the cultures at half-log dilutions and incubated at 37 C. The cul-






























3804 K.-J. Puan et al. / FEBS Letters 579 (2005) 3802–3806To quantitate bioactivity, the dilution of the bacterial supernatant or
sonicate that gave half-maximal proliferation was determined. The re-
ciprocal of the dilution gave the units of bioactivity. Therefore, one
unit of bioactivity was the antigen amount in 1 ml that gave half-
maximal antigen-induced proliferation of a Vc2Vd2 T cell clone. This
corresponds to an HMBPP concentration of 31.6 pM or 31.6 fmol/ml
and an IPP concentration of 3 lM or 3 nmol/ml. To control for vari-
ations in this assay (about 3-fold), a standard preparation of ethyl-
pyrophosphate that contained 12000 U/ml was assayed with each
experiment. Bioactivity values were adjusted relative to this standard.
Total bioactivity for a 1 L culture was the sum of the bioactivity pres-
ent in the bacterial sonicates and culture supernatants. For stationary
phase and late stationary phase cultures of wild-type E. coli, 77% and
95% of the bioactivity was in the supernatant, respectively. In the
DK310 LytBG120D (pTMV20KM) and DK310 LytBG120D ﬂdA
























































Fig. 1. The MEP (deoxyxylulose) pathway of isoprenoid biosynthesis
and the engineered biosynthesis of IPP from exogenous mevalonate [1–
4]. Proposed steps of ﬂavodoxin action at GcpE and possibly at LytB
are shown. MEP enzymes are also termed IspC (Dxr), IspD (YgbP),
IspE (YchB), IspF (YgbB), IspG (GcpE), and IspH (LytB). The
DK310 bacteria were transformed with a plasmid containing the genes
for the following mevalonate pathway enzymes: MVK, mevalonate
kinase; PMK, phosphomevalonate kinase; MDD, mevalonate diphos-
phate decarboxylase.3. Results and discussion
3.1. Substitution of aspartic acid for glycine at position 120 in
LytB in DK310 results in the loss of IPP but not DMAPP
synthesis
A point mutation was made in the lytB gene of DK310
pTMV22KM that lacks isopentenyl diphosphate isomerase
by chemical mutagenesis such that aspartic acid was substi-
tuted for glycine at residue 120. This residue is in an area that
is highly conserved between E. coli, Mycobacterium tuberculo-
sis, the cyanobacteria, Synechocystis, the plant, Adonis aestiva-
lis, and the apicomplexan parasite, Plasmodium falciparum and
near an additional area of conservation around the cysteine res-
idue 96 [4,24]. The mutant, DK310 LytBG120D pTMV22KM
(idi), can synthesize IPP in the presence of mevalonate
through the introduced mevalonate pathway enzymes and is
mevalonate dependent (Table 1). Since the mutant lacks iso-
pentenyl diphosphate isomerase, it cannot isomerize IPP to
DMAPP. This is the only way to interconvert IPP and
DMAPP in E. coli [25]. Based on this fact, we hypothesize that
the LytBG120D mutant must continue to synthesize DMAPP
but has lost the ability to synthesize IPP.
Consistent with this hypothesis, blocking the MEP pathway
with fosmidomycin prevented bacterial growth (Table 1).
Moreover, reintroduction of isopentenyl diphosphate isomer-
ase from Streptomyces sp. in DK310 LytBG120D pTMV20KM
(Table 1) restored mevalonate-independent growth and fosmi-
domycin resistance. Since DMAPP synthesized by LytB could
isomerize to IPP and IPP synthesized by phosphomevalonate
decarboxylase could isomerize to DMAPP, bacterial growth
occurred even when each individual pathway was blocked
(see Fig. 1).
3.2. Flavodoxin I is essential for isoprenoid biosynthesis
To examine genes that are involved in isoprenoid biosynthe-
sis, the DK310 LytBG120D pTMV20KM strain was subjected
to random transposon mutagenesis. Mevalonate was intro-
duced to rescue bacteria since mutations in the MEP pathway
are lethal in its absence. A total of 27 mutants were selected for
their failure to grow independently of MVA. Direct genome
sequencing of these mutants reveals that 25 had transposon
insertions in genes of enzymes within the MEP pathway.
One gene not previously reported to be essential in the MEP
pathway was ﬂdA. Mutation of ﬂdA, as with mutation of all
the genes present in the MEP pathway, resulted in the failureof the mutant to grow on LB agar unless exogenous mevalo-
nate was provided (Fig. 2B and C).
Since the functional activity of GcpE [7,15] and LytB
[8,16,17,26] depends on the availability of reduced [4Fe–4S]+
clusters, a defect in ﬂavodoxin I function appears to block
the regeneration of reduced clusters resulting in impaired iso-
prenoid biosynthesis. Despite the fact that there are 50
iron–sulfur proteins in the genome of E. coli [27], deletion of
ﬂavodoxin I was not lethal or bacteriostatic as long as exoge-
nous mevalonate was present (Fig. 2B and C). To verify that
this phenotype was not the result of a polar eﬀect of the trans-
poson insertion, the ﬂdA mutant was complemented with a
full-length copy of plasmid-encoded ﬂdA. Growth was ob-
served in the ﬂdA-complemented mutant in the absence of
mevalonate showing that isoprenoid biosynthesis through the
MEP pathway was restored (Fig. 2D, G, and H). These results
demonstrate that the essential role for ﬂavodoxin I is in the
MEP pathway for isoprenoid biosynthesis.
Fig. 2. Mevalonate-independent growth of DK310 LytBG120D (pTMV20KM) is lost after disruption of ﬂdA and restored after ﬂdA complementation.
Panels A–D: Growth of the E. coli strains (A) DK310 LytBG120D (pTMV20KM) (termed KM20 on left) and DK310 LytBG120D (pTMV20KM) Æ ﬂdA
(termed KM20 Æ ﬂdA on right) on medium (B) without mevalonate, (C) with mevalonate, and (D) without mevalonate after complementation of the
KM20 Æ ﬂdA strain with an episomal ﬂdA gene. Panels E–H:Growth of KM20 Æ ﬂdA onmedium (E) without mevalonate or after complementation with
an episomal ﬂdA gene (F) with mevalonate, (G) without mevalonate, and (H) without mevalonate but with ampicillin. Note that although
complementation of the KM20 Æ ﬂdA strain with an episomal ﬂdA gene restored growth without mevalonate, the growth of the complemented bacteria
























Fig. 3. Loss of ﬂavodoxin I in DK310 LytBG120D (pTMV20KM)
decreased HMBPP to the levels of wild-type E. coli as assessed by
bioactivity for Vc2Vd2 T cells. Wild-type E. coli, DK310 LytBG120D
(pTMV20KM), and DK310 LytBG120D (pTMV20KM) ﬂdA were
grown to late stationary phase. Bioactivity for Vc2Vd2 T cells was
quantitated for bacterial culture supernatants and sonicates using
Vc2Vd2 T cell clones in an in vitro proliferation assay. Note that the
greatly elevated bioactivity of DK310 LytBG120D (pTMV20KM) that
have been shown to be due to accumulation of HMBPP [11] was
reduced to wild-type levels. Since one unit of bioactivity corresponds
to an HMBPP concentration of 31.6 pM or 31.6 fmol/ml, wild-type
bacteria, DK310 LytBG120D (pTMV20KM), and DK310 LytBG120D
(pTMV20KM) ﬂdA had bioactivity equivalent to 0.6, 250.3, and
0.7 lmol of HMBPP, respectively.
K.-J. Puan et al. / FEBS Letters 579 (2005) 3802–3806 38053.3. HMBPP synthesis is ﬂdA-dependent
HMBPP is synthesized by GcpE and is the upstream inter-
mediate for IPP and DMAPP in the MEP pathway. HMBPP
is 30000-fold more antigenic for human Vc2Vd2 T cells stim-
ulation than IPP (data not shown and [11,28]). Synthesis of
HMBPP through two one-electron transfers catalyzed by the
[4Fe–4S] cluster of the GcpE enzyme has been proposed [9].
Like many [Fe–S] proteins, the enzymatic activity of GcpE de-
pends on the presence of a reducing system. The source of
these reducing equivalents is either derived from exogenous
reductants (dithiothreitol or deazaﬂavin) or the native endog-
enous ﬂavodoxin/ﬂavodoxin reductase/NADPH regeneration
system.
In the LytBG120D mutant, DK310 LytBG120D (pTM-
V20KM), HMBPP was overproduced resulting in a large in-
crease of bioactivity (436-fold) for Vc2Vd2 T cell as compared
to the wild-type E. coli (Fig. 3). This is consistent with previous
reports showing that lytB deletion blocks the downstream syn-
thesis of IPP and DMAPP causing HMBPP to accumulate [11]
and large increases in bioactivity for Vc2Vd2 T cells [10]. How-
ever, the loss of ﬂavodoxin I in the ﬂdA double mutant led to
wild-type levels of bioactivity for Vc2Vd2 T cells. Thus, the
loss of ﬂavodoxin greatly impairs the ability of GcpE to make
HMBPP suggesting that the ﬂavodoxin regeneration system is
critical for providing reducing equivalents for the [4Fe–4S]
cluster. Although greatly reduced, the bioactivity of the ﬂdA
double mutant is still higher than two corresponding gcpE
transposon mutants (<500 and 1044 U/L) and a gcpE deletion
mutant [29] suggesting that there may be some residual activity
of the GcpE enzyme. The LytB enzyme also depends on a[4Fe–4S] cluster for enzymatic activity so the loss of ﬂavodoxin
I may also aﬀect LytB function. In summary, the essential role
for ﬂavodoxin I is to provide reducing equivalents for the
[4Fe–4S] cluster of GcpE and possibly LytB. Both of these en-
zymes are critical for the growth of E. coli under aerobic con-
ditions in rich media.
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